Gelicon^® is a preparation of gemfibrozil. Gemfibrozil is a fibric acid derivative. It is a lipid regulating agent which decreases serum cholesterol and triglycerides. It decreases serum low density lipoprotein (LDL) fraction and very low density lipoprotein (VLDL) fraction. In addition gemfibrozil increases high density lipoprotein (HDL) cholesterol. Gemfibrozil inhibits peripheral lipolysis and decreases the hepatic extraction of free fatty acids, thus reducing hepatic triglyceride production. Gemfibrozil also inhibits synthesis of VLDL carrier apolipoprotein B,leading to decrease in VLDL production. How Gemfibrozil raises HDL concentration is not known. The drug may, in addition to elevate HDL cholesterol, reduce incorporation of long chain fatty acids into newly formed triglycerides, accelerate turn over and removal of cholesterol from the liver and increase excretion of cholesterol in the faeces.
 

Gelicon^® is used in the treatment of type IIa, type IIb, type III, type IV and type V hyperlipoproteinaemias.

• It is used in the treatment of adult patients with very high elevation of serum triglyceride levels (types IV and V hyperlipidemid) that presents a risks of pancreatitis and who don't responds adequately to a determined dietary effort to control them.
• It is indicated for the primary prevention of coronary heart diseases only in type IIb patients (in men between 40 and 55 years of age) without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents and who have following triad of lipid abnormalities: low HDL cholesterol levels in addition to elevated LDL cholesterol levels and elevated triglycerides.

Adult: The recommended dose for adults is 1200 mg daily in two divided doses 30 minutes before the morning and evening meal. The dosages range may vary between 900-1500 mg daily.
 

It is contraindicated in case of

• Alcoholism
• Hepatic impairment
• Severe renal dysfunction
• Pre-existing gallstones
• During pregnancy and lactation
   

Before initiating long-term treatment with gemfibrozil, lipid profile, blood counts, renal activity, annual eye examination and liver function tests should be done; preferably avoid use with statins (high risk of rhabdomyolysis).
 

Gastro-intestinal disturbances, rash, dermatitis, puritus, urticaria, impotence, headache, dizziness, blurred vision, cholestatic jaundice, angioedema, laryngeal oedema, atrial fibrillation, pancreatitis, myasthenia, myopathy, rhabdomyolysis, painful extremities, myalgia accompanied by increases in creatine kinase.
 

Safety in human pregnancy has not been established. It is not known whether gemfibrozil is secreted in human milk. Like most drugs, gemfibrozil should normally be avoided during pregnancy and lactation.

Store in a cool & dry place, away from light. Keep out of reach of children.

 

Gelicon^® 300 mg capsule: Box containing 6 strips of 4 capsules each. Each capsule contains gemfibrozil USP 300 mg.



Manufactured by:
ESKAYEF BANGLADESH LTD
DHAKA, BANGLADESH
® REGD.TRADEMARK